Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
PCR in Screening and Diagnostics: Market Developments, Growth Areas and Opportunities

Global PCR diagnostics market: $27 billion industry by 2015


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-02-18 02:31:01 - PCR in Screening and Diagnostics: Market Developments, Growth Areas and Opportunities - a new market research report on companiesandmarkets.com

This market analysis was carried out to provide business information to developers, manufacturers and suppliers in the PCR clinical and diagnostics field. Its findings include:- Marketing and sales opportunities
- End-user purchasing decisions
- Market growth and shrinkage
- Innovation and new product opportunitiesThis study was conducted through specialist groups of experienced clinical and laboratory PCR end-users and its findings are therefore based on ´real world´ market data. Market Analysis and Opportunities A competitive market analysis of current practices and future developments across 25 key market areas in the PCR screening and diagnostics field. Examples include- PCR Techniques: Which PCR screening and diagnostics techniques are the market leaders and what changes do end-users predict over the next three years. Which PCR clinical and

 

 

diagnostics techniques are growing and which are declining?- PCR Applications: Which PCR screening and diagnostics applications are the market leaders and what changes do end-users predict over the next three years. Which PCR clinical and diagnostics applications are growing and which are reducing?- Suppliers: Who are the major company suppliers in the PCR screening and diagnostics field and who do PCR clinical and diagnostics end-users plan to purchase from over the next three years. Who are the top ten suppliers in this field, and what changes are predicted over the next three years.- Opportunities: The findings of this study are analysed to identify opportunities to suppliers in the PCR screening and diagnostics field, in the ´Market Areas´ indicated below.
OverviewPCR is used in a wide variety of molecular biology applications, including sequencing, genetic fingerprinting, cloning, disease research, diagnostics, drug discovery, disease biomarkers and forensics. Today, this technique continues to grow and some estimates suggest that by 2015 global markets for this technique will exceed $27 billion. Biopharm Reports has carried out a market study of this field, which investigated the use of PCR in screening and diagnostics. This involved the participation of 173 specialist end-users in 50 countries. This study was carried out to identify market developments and growth areas, and the opportunities these offer to developers and vendors in this field.Market areas investigated in this study included current and future techniques and applications, PCR suppliers, end-users´ plans for using PCR in screening and diagnostics over the next three years, as well as the PCR companies they anticipate purchasing from. Other market areas included preferred PCR systems, new developments, emerging applications, the strengths and weaknesses of current systems, innovation, budgets and expenditure, consumables, software, sample preparation and other areas. Further details are presented below. Market Areas- Current PCR techniques: Current use of more than 40 PCR techniques in screening or diagnostics by end-users, each ranked according to their competitive position. PCR techniques considered include Allele Specific PCR, Arbitrarily Primed PCR (APPCR), Assembly PCR (Polymerase Cycling Assembly, PCA), Asymmetric PCR (A PCR), Bead Emulsion Amplification PCR (BEA), Classical PCR, Colony PCR, Degenerate Oligonucleotide PCR (DOPPCR), Digital PCR (dPCR), Helicase Dependent Amplification (HDA), Hot start PCR, Hyper PCR, Immunocapture PCR, In Silico PCR, Inter Sequence Specific PCR (ISSR), Inverse PCR, Ligation Mediated PCR, Long PCR, Loop Mediated Isothermal Amplification (LAMP), Methylation Specific PCR (MSP), Miniprimer PCR, Multiplex Ligation Dependent Probe Amplification (MLPA), Multiplex PCR, Nested PCR, Overlap Extension PCR ( Splicing by overlap extension, SOE), PANAC (Single Reaction Real Time PCR), PCR array, PCR Denaturing Gradient Gel Electrophoresis (PCR DGGE), PCR Restriction Fragment Length Polymorphism (PCRRFLP), Quantitative PCR (qPCR), Random Amplified Polymorphic DNA (RAPD), Rapid Amplification of cDNA ENDS PCR (RACE PCR), Reverse Transcription PCR (RTPCR), Single Molecule PCR, Single Specific Primer Polymerase, Chain Reaction (SSPPCR), Solid Phase PCR, Stem loop RT PCR, Stepdown PCR, Taqman, Temporal Temperature Gradient Gel Electrophoresis (PCRTTGE), Thermal Asymmetric Interlaced PCR (TAILPCR), Touchdown PCR, Universal Fast Walking or other. - Future PCR techniques: Future anticipated use of more than 40 PCR techniques in screening or diagnostics by end-users over the next three years, each ranked according to their competitive position. PCR techniques considered include Allele Specific PCR, Arbitrarily Primed PCR (APPCR), Assembly PCR (Polymerase Cycling Assembly, PCA), Asymmetric PCR (A PCR), Bead Emulsion Amplification PCR (BEA), Classical PCR, Colony PCR, Degenerate Oligonucleotide PCR (DOPPCR), Digital PCR (dPCR), Helicase Dependent Amplification (HDA), Hot start PCR, Hyper PCR, Immunocapture PCR, In Silico PCR, Inter Sequence Specific PCR (ISSR), Inverse PCR, Ligation Mediated PCR, Long PCR, Loop Mediated Isothermal Amplification (LAMP), Methylation Specific PCR (MSP), Miniprimer PCR, Multiplex Ligation Dependent Probe Amplification (MLPA), Multiplex PCR, Nested PCR, Overlap Extension PCR ( Splicing by overlap extension, SOE), PANAC (Single Reaction Real Time PCR), PCR array, PCR Denaturing Gradient Gel Electrophoresis (PCR DGGE), PCR Restriction Fragment Length Polymorphism (PCRRFLP), Quantitative PCR (qPCR), Random Amplified Polymorphic DNA (RAPD), Rapid Amplification of cDNA ENDS PCR (RACE PCR), Reverse Transcription PCR (RTPCR), Single Molecule PCR, Single Specific Primer Polymerase, Chain Reaction (SSPPCR), Solid Phase PCR, Stem loop RT PCR, Stepdown PCR, Taqman, Temporal Temperature Gradient Gel Electrophoresis (PCRTTGE), Thermal Asymmetric Interlaced PCR (TAILPCR), Touchdown PCR, Universal Fast Walking or other. - Current PCR applications: Current use of 15 PCR applications in screening or diagnostics by end-users, each ranked according to their competitive position.Application considered were allele size detection for human ID STR typing, bacterial tipification (REPPCR), cell-free DNA mutations, cloning, commensal bacteria detection / quantification, community profiling, detection of antimicrobial resistance genes, detection of specific microbial 16S rRNA genes, diagnostics, drug treatment dosage prediction, drug treatment type prediction, fungal species detection, gene expression (mRNA), gene mutations and alterations, generating genetic probes, genetic mapping, genetic material amplification, sequencing, haplotypes, immunocapture PCR mediated virion detection, microbial populations, MicroRNA quantification, pathogen detection/identification, quantitative analysis of gene abundance, site-directed mutagenesis, tissue typing or other.- Future PCR applications: Application considered were allele size detection for human ID STR typing, bacterial tipification (REPPCR), cell-free DNA mutations, cloning, commensal bacteria detection / quantification, community profiling, detection of antimicrobial resistance genes, detection of specific microbial 16S rRNA genes, diagnostics, drug treatment dosage prediction, drug treatment type prediction, fungal species detection, gene expression (mRNA), gene mutations and alterations, generating genetic probes, genetic mapping, genetic material amplification, sequencing, haplotypes, immunocapture PCR mediated virion detection, microbial populations, MicroRNA quantification, pathogen detection/identification, quantitative analysis of gene abundance, site-directed mutagenesis, tissue typing or other.- Biomarker identity: The identities of the main biomarkers investigated using PCR. - Biomarker types: The main biomarker types investigated using PCR, including gene variations (mutations/polymorphisms), DNA methylation, gene copy number, gene expression, SNPs, mRNA, MicroRNA, alternative spliced variants or other. - Biomarker utility: The main clinical utilities of biomarkers investigated using PCR, including disease prognosis, disease susceptibility or risk, disease stage or severity, drug type therapy decision-making, drug type therapy dose, drug discovery, early detection of disease, clinical trial endpoint, guiding treatment, response to therapy, safety or toxicity factors or other areas. - Current company suppliers: End-users´ preferred current company suppliers for their PCR, including Abbott, Agilent, Applied Biosystems, Becton Dickinson, Bioline, Biometra, Biorad, Biotium, Biozyme, Cepheid, Eppendorf, ESCO, Euroclone, Eurogentec, Fermentas, Finnzymes, Fluidigm, GE Healthcare, Genework, Hain Life sciences, Idaho, Integrated Data Technologies, Invitrogen, KapaBiosystems, Life Technologies, Luminex, Machery Nagel, MJ Research, New England BioLabs, Perkin Elmer, Promega, Qiagen, Quanta Bioscience, Roche, SensoQuest, Siemens, Sigma Genosys, Stratagene, Takara, Thermofisher or others. - Future company suppliers: End-user´s anticipated preferred company suppliers for their PCR over the next three years, including Abbott, Agilent, Applied Biosystems, Becton Dickinson, Bioline, Biometra, Biorad, Biotium, Biozyme, Cepheid, Eppendorf, ESCO, Euroclone, Eurogentec, Fermentas, Finnzymes, Fluidigm, GE Healthcare, Genework, Hain Life sciences, Idaho, Integrated Data Technologies, Invitrogen, KapaBiosystems, Life Technologies, Luminex, Machery Nagel, MJ Research, New England BioLabs, Perkin Elmer, Promega, Qiagen, Quanta Bioscience, Roche, SensoQuest, Siemens, Sigma Genosys, Stratagene, Takara, Thermofisher or others. - Preferred instrument: End-users preferred PCR instrument (from their preferred supplier) in the PCR field.- Strengths: The strengths of end-user´s preferred instrument in the PCR field (how is it meeting their needs in this area).- Weaknesses: The weaknesses of end-users preferred instrument in the PCR field (how is it failing to meet their needs in this area).- Bioinformatics software: End-users preferred bioinformatics software in the PCR field.- Required innovations: End-user´s views (rated on a scale of 1-10) on the PCR areas where innovations is most required. Innovation areas considered were sample preparation, ancillary techniques, PCR (qualitative) selectivity, PCR (quantitative) sensitivity, PCR reproducibility, PCR qualitative/quantitative capability, PCR robustness (ruggedness), detection methods, automation, speed or sample throughput, specialist data control systems, specialist bioinformatics systems or other.- Samples: End-user´s main samples analysed using PCR, including animal tissues, cell isolates, cells cerebrospinal fluid, genetic material, human tissues, In-vitro biological solutions, microbiological materials, plasma, saliva, serum, urine, whole blood or other. - Sample preparation: End-user´s preferred sample preparation technique.- Recent Innovation: End-user´s views on the most important PCR innovations in their field over the last three years.- Financial Budget: End-user´s annual financial budgets relating to their use of PCR in screening and diagnostics.- Cost per sample: End-users average costs per sample, using PCR in screening and diagnostics.- Current Budget breakdown: End user´s current budget breakdown for the use of PCR in screening and diagnostics, relating to reagents and consumables, system control (data handling) software, data analysis (offline) software, PCR instruments, sample preparation and related instrumentation, ancillary systems/instrumentation, general overheads, instrument servicing/repair, staff salaries and other areas. - Future Budget breakdown: End user´s anticipated future budget breakdown for the use of PCR in screening and diagnostics, relating to reagents and consumables, system control (data handling) software, data analysis (offline) software, PCR instruments, sample preparation and related instrumentation, ancillary systems/instrumentation, general overheads, instrument servicing/repair, staff salaries and other areas. - Overall budget: End-user´s estimates of by how much they anticipate their overall annual financial budget for the use of PCR in screening and diagnostics will change, either increase or decrease, over the next three years.- Consumables: End-users top three consumables in terms of overall costs, that are directly associated with their PCR work in screening and diagnostics. - PCR activities: End-user´s PCR activities in screening and diagnostics, relating to the running of routine PCR tests for clinical decision-making, the development or validation of PCR tests and the qualitative discovery of disease biomarkers using PCR.- Organisation types: Organisation types in this study included universities, research Institutes, small companies, medium sized companies, large international company, clinics, hospitals, government organisations, veterinary organisation and others. - Fields: Fields types of participants in this study included biotechnology, clinical, hospital, government, healthcare, pharmaceuticals, research institute, university or other.- Therapeutic Areas: End-users´ DNA sequencing activities in terms of their general therapeutic area, including arthritis, autoimmune diseases, done metabolism, cancer, cardiovascular, central nervous system, endocrine, gastrointestinal, genito-urinary system, haematology, infections, inflammation, metabolic disorders, musculoskeletal disorders, nutrition, obstetrics and gynaecology, ophthalmology, pain, respiratory, skin or other. - Purpose: End-users´ underlying reasons for using PCR in screening or diagnostics across 12 areas, namely clinical research, routine diagnostics, routine screening, clinical trials, treatment decisions, treatment monitoring, diagnostics research, disease research, drug R&D, drug targets, pathology, toxicology or other.

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com